BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

UCB SA 

Allée de la Recherche, 60

Brussels    1070  Belgium
Phone: 32-2-559-9999 Fax: 32-2-559-9900


SEARCH JOBS




Industry
Biotechnology






 Company News
UCB SA Terminates $1.53 Billion Sale Of Generic Drug Unit To Buyout Firms 12/17/2014 6:24:18 AM
Illinois-Based Akorn, Inc. (AKN) Eyes $2 Billion UCB SA Unit In Potential Tax Inversion Deal 9/12/2014 6:38:34 AM
UCB SA to Enhance Informatics Environment With Dotmatics' Vortex 8/7/2013 9:42:46 AM
Immunomedics, Inc. (IMMU) and UCB SA Announce Restructuring of Epratuzumab License Agreement for Up to $60 Million 12/28/2011 7:49:24 AM
UCB SA Release; Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) C-V Reduced Seizure Frequency and Severity and Improved Health-related Quality of Life Measures 12/5/2011 12:34:12 PM
UCB SA Pleads Guilty to Illegal Off-Label Marketing of Epilepsy Drug Keppra; to Pay $34.4 Million 6/9/2011 10:24:03 AM
UCB SA Plans EUR250M ($334M) Plant To Meet Cimzia Demand 1/3/2011 11:44:01 AM
Actient Pharmaceuticals LLC Inks Deal with UCB SA for Marketed Drugs with Global Sales of $53M 7/30/2010 7:25:22 AM
UCB SA And Immunomedics, Inc. (IMMU) Release: New Data From EMBLEM(TM) Study Show Pipeline Drug Epratuzumab Provided Significant Efficacy for Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus 6/16/2010 8:34:52 AM
UCB SA Subsidiary, Schwarz Pharma, To Pay $22M In False Claims Settlement 4/30/2010 8:17:37 AM
12